Involvement of interleukin‐1 in the inflammatory actions of aminobisphosphonates in mice
- 1 August 2000
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 130 (7), 1646-1654
- https://doi.org/10.1038/sj.bjp.0703460
Abstract
Aminobisphosphonates (aminoBPs) are potent inhibitors of bone resorption. However, they cause undesirable inflammatory reactions, including fever, in humans. Intraperitoneal injection of aminoBPs into mice also induces inflammatory reactions, including a prolonged elevation of the activity of the histamine-forming enzyme, histidine decarboxylase (HDC). Because interleukin-1 (IL-1) is a typical pyrogen and a strong inducer of HDC, we examined whether aminoBPs induce inflammatory reactions in mice deficient in genes for both IL-1alpha and IL-1beta (IL-1-KO mice). In control mice, aminoBPs induced an elevation of HDC activity and other inflammatory reactions (enlargement of the spleen, atrophy of the thymus, exudate in the thorax and increase in granulocytic cells in the peritoneal cavity). These responses were all weak or undetectable in IL-1-KO mice. We have previously shown that lipopolysaccharides (LPSs) from Escherichia coli and Prevotella intermedia (a prevalent gram-negative bacterium both in periodontitis and endodontal infections) are capable of inducing HDC activity in various tissues in mice. In control mice treated with an aminoBP, the LPS-induced elevations of serum IL-1 (alpha and beta) and tissue HDC activity were both markedly augmented. However, such an augmentation of HDC activity was small or undetectable in IL-1-KO mice. These results, taken together with our previous findings (i) suggest that IL-1 is involved in the aminoBP-induced inflammatory reactions and (ii) lead us to think that under some conditions, inflammatory reactions induced by gram-negative bacteria might be augmented in patients treated with an aminoBP. In this study, we also obtained a result suggesting that IL-1-deficiency might be compensated by a second, unidentified, mechanism serving to induce HDC in response to LPS when IL-1 is lacking.Keywords
This publication has 80 references indexed in Scilit:
- Mechanism of Aminobisphosphonate Action: Characterization of Alendronate Inhibition of the Isoprenoid PathwayBiochemical and Biophysical Research Communications, 1999
- Nitrogen-Containing Bisphosphonates as Carbocation Transition State Analogs for Isoprenoid BiosynthesisBiochemical and Biophysical Research Communications, 1999
- Farnesyl Pyrophosphate Synthase Is the Molecular Target of Nitrogen-Containing BisphosphonatesBiochemical and Biophysical Research Communications, 1999
- Nitrogen-Containing Bisphosphonates Inhibit Isopentenyl Pyrophosphate Isomerase/Farnesyl Pyrophosphate Synthase Activity with Relative Potencies Corresponding to Their Antiresorptive Potenciesin Vitroandin VivoBiochemical and Biophysical Research Communications, 1999
- Production of Mice Deficient in Genes for Interleukin (IL)-1α, IL-1β, IL-1α/β, and IL-1 Receptor Antagonist Shows that IL-1β Is Crucial in Turpentine-induced Fever Development and Glucocorticoid SecretionThe Journal of Experimental Medicine, 1998
- Inhibition of antigen-presenting cell function by alendronate in vitroJournal of Bone and Mineral Research, 1995
- Interleukin 3 Promotes Histamine Synthesis in Hematopoietic Progenitors by Increasing Histidine Decarboxylase mRNA ExpressionBiochemical and Biophysical Research Communications, 1993
- Comparison of the Distribution of Three Bisphosphonates in MiceBasic & Clinical Pharmacology & Toxicology, 1990
- Macrophages can produce factors capable of inducing histidine decarboxylase, a histamine-forming enzyme, in vivo in the liver, spleen, and lung of miceCellular Immunology, 1986
- A New Method for the Extraction of R LipopolysaccharidesEuropean Journal of Biochemistry, 1969